Our in vitro assays of tumor-primed NK cell alloreactivity to normal hemopoieitic stem cells in the preclinical phase and during this trial showed no lysis or suppression of normal CD34+ bone marrow cells. This evidence concerns the gene CD34 and neoplasm.